The field of cancer immunology has undergone significant transformation over the past decade, reshaping our understanding of tumor–immune system ...

FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). This is an ASCO Meeting Abstract from the 2024 ...

Rapid Response Monitoring and KEYTH Security, a residential and commercial security company, announced a partnership with Ubiety Technologies to become the first to launch the Ubiety Halo platform and ...

Innate lymphoid cells, which curiously behave like T cells even though they don’t recognize specific antigens, show promise as a potential cancer therapeutic. In the years that followed, other groups ...

AI-Evolved Adaptive Robot Is Nearly Impossible to Destroy Robots have long been designed around a simple assumption: their bodies and ...

A new study shows p62-mediated Mallory-Denk body formation is an adaptive, protective response to alcohol-induced liver ...

TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with ...